Chemotherapy :: Role of antioxidants in reducing chemotherapy toxicity

A new study showing a reduction in the toxic side effects of ROS-generating chemotherapies with concurrent antioxidant supplementation will be presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) that takes place June 1-5 at McCormick Place in Chicago.

Hepatitis C :: Schering-Plough presenting Hepatitis C at Digestive Disease Week 2007 Annual Meeting

A total of 20 oral and poster presentations on clinical studies with Schering-Plough’s hepatitis products, including PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for chronic hepatitis C virus (HCV) infection, as well as boceprevir (SCH 503034), the company’s investigational oral HCV protease inhibitor currently in Phase II clinical development, will be presented by leading researchers at the 38th annual Digestive Disease Week (DDW) meeting to be held at the Washington Convention Center in Washington, D.C., May 20-23.

Do NOT follow this link or you will be banned from the site!